en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Data › Receptor Action And Pharmacokinetics — Field Notes

Receptor Action And Pharmacokinetics — Field Notes

By Editorial Desk · published 2025-08-13 · last reviewed 2025-09-17 · Data

lyophilisation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-17. Anything still debated is marked as such rather than presented as settled.

Receptor Action and Pharmacokinetics

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

Background and Receptor Mechanism

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorG-protein-coupled receptor on pituitary somatotrophs
Half-life, long-acting formSeveral daysExtended by covalent albumin binding
Half-life, short formAbout 30 minutesCleared rapidly by peptidases and kidneys
Route in studiesSubcutaneous injectionUsed in the published human trials
Main measured effectRise in GH and IGF-1Surrogate markers rather than clinical endpoints

CJC-1295 Structure And Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Related pages on this site

Handling, Stability and Analysis

Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Molecular Background and Naming

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

Background and Molecular Design

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Notes from published material

The nine eastern lowland departments, comprising about 54% of Colombia's area, have less than 6% of the population. Traditionally a rural society, movement to urban areas was very heavy in the mid-20th century, and Colombia is now one of the most urbanized countries in Latin America. The urban population increased from 31% of the total in 1938 to nearly 60% in 1973, and by 2014 the figure stood at 76%. The population of Bogotá alone has increased from just over 300,000 in 1938 to approximately 8 million today. In total 72 cities now have populations of 100,000 or more (2015). As of 2012 Colombia has the world's largest populations of internally displaced persons (IDPs), estimated to be up to 4.9 million people. The life expectancy was 74.8 years in 2015, and infant mortality was 13.1 per thousand in 2016. In 2015, 94.58% of adults and 98.66% of youth are literate and the government spends about 4.49% of its GDP on education. Colombia is a highly urbanized country with 77.1% of the population living in urban areas. The largest cities in the country are Bogotá, with 7,387,400 inhabitants, Medellín, with 2,382,399 inhabitants, Cali, with 2,172,527 inhabitants, and Barranquilla, with 1,205,284 inhabitants.

Reiko Nagatsuki (長月 礼子, Nagatsuki Reiko) Voiced by: Misato Matsuoka Member of the Agency Autumn Division's Security Department. She is responsible for the Town of Autumn's security system. She is an intelligent woman with a career that allows her to operate flexibly. She considers Rindo a little brother. Ishihara (石原, Ishihara) Voiced by: Haruna Mikawa (Japanese); Cassie Ewulu (English) An employee of the Agency of the Four Seasons' Security Department. She is assigned to the Agent of Winter's security and also serves as Rousei's psychologist. She is a calm woman with excellent qualities in her duties.

=== LGR4 === LGR4 binds R-spondins to activate the Wnt signaling pathway. Wnt signaling regulates bone mass and osteoblast differentiation and is important for the development of bone, heart, and muscle. An LGR4 nonsense mutation in a healthy population has been linked to low bone mass density and symptoms of osteoporosis. LGR4 mutant mice showed the observed low bone mass is not due to age-related bone loss. Mutations in LGR4 have been associated with family lineages with medical histories of rare bone disorders. Wild-type mice lacking LGR4 also displayed delayed osteoblast differentiation during development, showcasing the important role of LGR4 in bone mass regulation and development.

Sources: en.wikipedia.org

Further detail

The National Institute for Health and Clinical Excellence (NICE), UK released updated diabetes recommendations on 30 May 2008, which recommend that self-monitoring of plasma glucose levels for people with newly diagnosed type 2 diabetes must be integrated into a structured self-management education process. The recommendations have been updated in August 2015 for children and young adults with type 1 diabetes. The American Diabetes Association (ADA), which produces guidelines for diabetes care and clinical practice recommendations, recently updated its "Standards of Medical Care" in January 2019 to acknowledge that routine self-monitoring of blood glucose in people who are not using insulin is of limited additional clinical benefit. A randomized controlled trial evaluated once-daily self-monitoring that included tailored patient messaging and did not show that this strategy led to significant changes in A1C after a year. Media related to Blood glucose monitoring at Wikimedia Commons

It is a bioactive sphingoid which derives from the sphinganine. It is formed by a sphingoid and an amino alcohol and it constitutes the conjugated base of 1-deoxymethylsphinganine (1+). Its role is accepting a hydron from a donor via its organic amino compound; it is a Brønsted base. It is also known as deoxymethyl-SA, (2R)-1-aminoheptadecan-2-ol and 1-desoxymethylsphinganine. The molecular weight of this compound is 271,48 g/mol and its molecular formula is C17H37NO, which means it has 17 carbons. In relation to its appearance, it has a powder form. Other physical and chemical properties are not certainly known.

32. ArXiv [Preprint]. 2026 Sep 17:arXiv:2609.05858v2. Fluidization in Growth-Induced Morphogenesis. Wu M. Elastic buckling has explained shape formation in growing tissues, yet the role of tissue fluidity remains elusive. We derive a minimal fluidized growth-elasticity model as a nonlinear analogue of Maxwell rheology. Analysis of a growing strip reveals a different picture of growth-induced morphogenesis: rather than emerging at a critical stress, symmetry breaking develops continuously during growth. Fluidity regulates stress evolution, the rate of shape-symmetry breaking, and flow patterns, establishing it as an active regulator of morphogenesis beyond its intuitive role in stress relaxation. PMCID: PMC13596616

Sources: en.wikipedia.org

Supporting material

At the 2010 panel, three panelists voted that the existing warnings were good enough; two were back in 2013. Seven voted to make those warnings more onerous, and five of them returned. But of the 10 who voted to restrict Avandia's use, only four returned. And of the 12 who voted in 2010 to withdraw Avandia from the market, only three came back.

==== United States ==== Phenylethylamine is not a scheduled substance in the United States. However, at least one person in the United States has been prosecuted under the Federal Analogue Act for selling phenylethylamine with the prosecutions argument that PEA is a structural analog of amphetamine and methamphetamine.

Following the Viet Minh's defeats on the Hanoi perimeter, De Lattre decided to seize the city of Hòa Bình, 20 miles (32 km) west of the De Lattre Line, in an attempt to hinder the flow of supplies between Tonkin, which received direct Chinese support, and central and southern Vietnam. It also aimed to maintain the allegiance of the Muong troops. The city was captured by a parachute drop on November 14. The ensuing battle became increasingly costly to the French and after De Lattre fell ill from cancer and returned to Paris for treatment where he would die shortly thereafter in January 1952, his replacement as the overall commander of French forces in Indochina, General Raoul Salan, decided to pull back from the Hòa Bình salient. The French lost nearly 5,000 men and the Viet Minh "at least that number" according to historian Phillip P. Davidson, while Spencer C. Tucker claims 894 French killed and missing and 9,000 Viet Minh casualties. This campaign showed that the war was far from over. Throughout the war theater, the Việt Minh cut French supply lines and wore down the resolve of the French forces. There were continued raids, skirmishes and guerrilla attacks, but through most of the rest of the year each side withdrew to prepare for larger operations. In the Battle of Nà Sản, starting on October 2, French commanders began using "hedgehog" tactics, consisting in setting up well-defended outposts to get the Việt Minh out of the forests and force them to fight conventional battles instead of using guerrilla tactics.

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 raise growth hormone levels?

It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.

Why does the DAC form last longer?

The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.

What remains uncertain about its effects?

Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

Network